Effects of HMG-CoA reductase inhibitor on hemostasis

被引:48
作者
Koh, KK [1 ]
机构
[1] Gachon Med Sch, Ctr Heart, Div Cardiol, Inchon 405760, South Korea
关键词
lipid-lowering therapy; atherosclerosis; coagulation; fibrinolysis; platelet; viscosity;
D O I
10.1016/S0167-5273(00)00325-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) therapy have demonstrated improvement in coronary atherosclerosis progression and reduction in risk of cardiovascular events. However, improvement in cardiovascular end-points is incompletely explained by the baseline or treated LDL cholesterol level. The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify hemostasis. Local activation of platelets and thrombus formation adjacent to atheromatous plaques, especially where ruptured or eroded, are now recognized to be of pathophysiological importance in the acute and chronic clinical expression of coronary heart disease. Thus, favorable effects of statins on hemostasis may be relevant to decreasing or delaying the progression and clinical manifestations of atherosclerosis. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:23 / 32
页数:10
相关论文
共 98 条
[61]   ENZYME CASCADE IN BLOOD CLOTTING MECHANISM + ITS FUNCTION AS BIOCHEMICAL AMPLIFIER [J].
MACFARLANE, RG .
NATURE, 1964, 202 (493) :498-&
[62]   Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia [J].
Marais, AD ;
Firth, JC ;
Bateman, ME ;
Byrnes, P ;
Martens, C ;
Mountney, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (08) :1527-1531
[63]   EFFECTS OF LONG-TERM TREATMENT WITH LOVASTATIN ON THE CLOTTING SYSTEM AND BLOOD-PLATELETS [J].
MAYER, J ;
ELLER, T ;
BRAUER, P ;
SOLLEDER, EM ;
SCHAFER, RM ;
KELLER, F ;
KOCHSIEK, K .
ANNALS OF HEMATOLOGY, 1992, 64 (04) :196-201
[64]   Thrombotic thrombocytopenic purpura and simvastatin [J].
McCarthy, LJ ;
Porcu, P ;
Fausel, CA ;
Sweeney, CJ ;
Danielson, CFM .
LANCET, 1998, 352 (9136) :1284-1285
[65]   FIBRINOLYTIC-ACTIVITY, CLOTTING FACTORS, AND LONG-TERM INCIDENCE OF ISCHEMIC-HEART-DISEASE IN THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
RUDDOCK, V ;
STIRLING, Y ;
CHAKRABARTI, R ;
MILLER, GJ .
LANCET, 1993, 342 (8879) :1076-1079
[66]   HEMOSTATIC FUNCTION AND ISCHEMIC-HEART-DISEASE - PRINCIPAL RESULTS OF THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
BROZOVIC, M ;
CHAKRABARTI, RR ;
HAINES, AP ;
IMESON, JD ;
MELLOWS, S ;
MILLER, GJ ;
NORTH, WRS ;
STIRLING, Y ;
THOMPSON, SG .
LANCET, 1986, 2 (8506) :533-537
[67]   EFFECTS OF ESTROGEN OR ESTROGEN/PROGESTIN REGIMENS ON HEART-DISEASE RISK-FACTORS IN POSTMENOPAUSAL WOMEN - THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL [J].
MILLER, VT ;
LAROSA, J ;
BARNABEI, V ;
KESSLER, C ;
LEVIN, G ;
SMITHROTH, A ;
GRIFFIN, M ;
STOY, DB ;
BUSH, T ;
ZACUR, H ;
FOSTER, D ;
ANDERSON, J ;
MCKENZIE, A ;
MILLER, S ;
WOOD, PD ;
STEFANICK, ML ;
MARCUS, R ;
AKANA, A ;
HEINRICHS, L ;
KIRCHNER, C ;
OHANLAN, K ;
RUYLE, M ;
SHEEHAN, M ;
JUDD, HL ;
GREENDALE, G ;
BAYALOS, R ;
LOZANO, K ;
KAWAKAMI, K ;
BARRETTCONNOR, E ;
LANGER, R ;
KRITZSILVERSTEIN, D ;
CARRIONPETERSEN, ML ;
CAVERO, C ;
SCHROTT, HG ;
JOHNSON, SR ;
FEDDERSEN, DA ;
KRUTZFELDT, DL ;
BENDA, JA ;
PAUERSTEIN, C ;
TRABAL, J ;
SCHENKEN, R ;
STERN, MP ;
RODRIGUEZSIFUENTES, M ;
EASTON, C ;
WELLS, HB ;
ESPELAND, M ;
HOWARD, G ;
BYINGTON, R ;
LEGAULT, C ;
SHUMAKER, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (03) :199-208
[68]  
Mitropoulos KA, 1997, EUR HEART J, V18, P235
[69]  
NEMERSON Y, 1988, BLOOD, V71, P1
[70]   Effect of ω-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia [J].
Nordoy, A ;
Bonaa, KH ;
Sandset, PM ;
Hansen, JB ;
Nilsen, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) :259-265